A treatment for HER2-positive cancer from an unknown origin
Part of Cancer clinical trials.
This trial tests a combination of two drugs for a cancer that doctors cannot find where it started (cancer of unknown primary). The drugs target a protein called HER2, which is found on the surface of some cancer cells, to help stop the cancer from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed cancer of unknown primary that is HER2-positive (IHC 2+ or 3+).
- You must have had at least one prior treatment for your cancer that did not work or stopped working.
- You must be willing to provide a tumor sample for testing (paraffin block, sections, or fresh tissue).
- You must have measurable disease that has progressed after your most recent treatment.
- You must be in generally good health with no severe heart, lung, or immune system problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people with cancer of unknown primary (CUP), meaning cancer that started in an unknown place in the body. It aims to use advanced genomic testing (looking at your tumor's DNA) on your stored tumor sample and blood to find clues about where the cancer began and possible treatment options.
This trial tests a radioactive medicine (Lu-177 FAP-2286) that seeks out and delivers radiation directly to cancer cells. It is for people whose cancer started in an unknown place and has not responded to their first chemotherapy.
This trial tests two drugs together: MRG003 (a targeted therapy that delivers chemo directly to EGFR-positive cancer cells) and pucotenlimab (an immunotherapy that helps your immune system attack the cancer). It is for people with a rare and aggressive thyroid cancer (ATC or PDTC) whose tumors have the EGFR protein and have grown despite previous treatment.
This trial tests a combination of two new drugs—an immunotherapy and an antibody-drug conjugate—for people with advanced squamous cell carcinoma of the skin. The goal is to see if this combo can shrink tumors and slow the cancer.
This trial tests a new combination of drugs for people with HER2-positive early breast cancer whose tumors did not respond well to the first round of standard targeted therapy plus chemo. The goal is to see if switching to trastuzumab-rezetecan plus pertuzumab or a different chemo combo (nab-paclitaxel, carboplatin, trastuzumab, and pyrotinib) can shrink the tumor before surgery.
This trial tests a combination of two drugs, trastuzumab deruxtecan (SHR-A1811) and pertuzumab, given before surgery to shrink HER2-positive breast cancer. It is for women with stage II or III breast cancer who have not yet had treatment and are in good overall health.
Hear when a new Cancer of Unknown Primary trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.